News and Information


Experimental Drug Prevents Doxorubicin from Harming the Heart

POSTED: April 06, 2020

An illustration displaying the experimental drug BAI1 (yellow) which inhibits the BAX protein using a novel binding site (green) and prevents the death of heart cells.The chemotherapy drug doxorubicin is used to treat many types of cancer, but some patients who receive the drug develop heart problems. Using new insights into how doxorubicin damages the heart, researchers have identified an experimental drug that may help protect the heart.

Read the NCI Cancer Currents Blog article

Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments

POSTED: September 21, 2018

In June, approximately 100 researchers attended a workshop on the campus of the National Institutes of Health (NIH) in Bethesda, MD, about an important but underappreciated side effect of some treatments for cancer: heart problems.

Read the NCI Cancer Currents Blog article

Higher Risk of Heart Failure Seen in Some Cancers

POSTED: March 26, 2018

Within 5 year of diagnosis, people treated for lymphoma or breast cancer were 3 times as likely to develop heart failure as people who never had cancer.Some people who have been treated for breast cancer or lymphoma have a higher risk of developing congestive heart failure than people who haven't had cancer, results from a new study show.

The study researchers retrospectively compared heart failure rates in people who were diagnosed with breast cancer or lymphoma with those in people who did not have cancer.

Read the NCI Cancer Currents Blog article

Encouraging A Single Core Lab for Echocardiogram Results

PUBLISHED: March 2018

This article summarizes a study funded by the NCI Division of Cancer Prevention to determine the reproducibility of cardiac safety assessments across two academic echocardiography core laboratories (ECLs), (Duke and the University of Pennsylvania), for echocardiograms (ECHOs) obtained in trials active in the community oncology setting.

Read the Science Direct article

Study Identifies Potential Cause of Hearing Loss from Cisplatin

A slide displaying how chemotherapy drug cisplatin (in green) occurs in a mouse inner ear.
POSTED: January 26, 2018

Results from a new study may explain why many patients treated with the chemotherapy drug cisplatin develop lasting hearing loss.

Researchers found that, in both mice and humans, cisplatin can be found in the cochlea—the part of the inner ear that enables hearing—months and even years after treatment. By contrast, the drug is eliminated from most organs in the body within days to weeks after being administered.

Read the NCI Cancer Currents Blog article

Acupuncture May Reduce Treatment-Related Joint Pain for Breast Cancer Patients

POSTED: January 08, 2018An image of acupuncturist inserting a needle into a patient.

Acupuncture can reduce joint pain caused by drugs called aromatase inhibitors, according to results from a large, rigorous study of this approach in postmenopausal women with early-stage breast cancer.

Read the NCI Cancer Currents Blog article

Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis

POSTED: August 25, 2017 4.7% of study participants with cancer had a heart attack or stroke within 6 months of diagnosis; 2.2% of participants without cancer had a heart attack or stroke within the same 6-month period.

A diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months following the diagnosis, findings from a new study suggest.

Read the NCI Cancer Currents Blog article

Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications

POSTED: January 30, 2017

In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.

Read the NCI Cancer Currents Blog article

Pre-Application Webinars for RFA-CA-17-052

"Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)"

Cover slide for RFA-CA-17-52.

NCI Listens — Slides Available

Cancer Moonshot Blue Ribbon PanelMaterials are now available from NCI Listens: Identifying Opportunities for Symptom Management Research in Response to Blue Ribbon Report (PPT, 1.44MB), a webinar lead by Dr. Ann O’Mara, Head, Palliative Care Research in the Division of Cancer Prevention (DCP), and other DCP staff, DCP was interested in hearing from the extramural research and patient advocate community regarding knowledge gaps and priorities for symptom management research, particularly as it pertains to understanding the mechanisms of cancer and treatment related symptoms and adverse events/toxicities that patients report when enrolled in clinical trials.